At the time of writing, Seres Therapeutics Inc [MCRB] stock is trading at $1.14, up 6.54%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MCRB shares have gain 9.62% over the last week, with a monthly amount drifted -0.87%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference. In a post published today on Yahoo Finance, Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET.
From an analyst’s perspective:
Previously, JP Morgan started tracking the stock with Neutral rating on April 21, 2023, and set its price target to $7. On July 23, 2021, downgrade downgraded it’s rating to Sell and revised its price target to $7 on the stock. Chardan Capital Markets upgraded its rating to a Buy but $30 remained the price target by the analyst firm on March 05, 2021. Chardan Capital Markets downgraded its rating to Neutral for this stock on September 18, 2020, and downed its price target to $27.50. In a note dated August 18, 2020, Piper Sandler initiated an Overweight rating and provided a target price of $40 on this stock.
For the past year, the stock price of Seres Therapeutics Inc fluctuated between $0.91 and $6.87. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $1.14 at the most recent close of the market.
Analyzing the MCRB fundamentals
According to Seres Therapeutics Inc [NASDAQ:MCRB], the company’s sales were 127.24M for trailing twelve months, which represents an -91.00% plunge. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0867 points at the first support level, and at 1.0333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1767, and for the 2nd resistance point, it is at 1.2133.
Seres Therapeutics Inc [MCRB] reported earnings per share of -$0.37 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.5/share, meaning a difference of $0.13 and a surprise factor of 26.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.36 per share as compared to estimates of $0.53 per share, a difference of -$0.17 representing a surprise of -32.10%.
Ratios To Look Out For
It is important to note that Seres Therapeutics Inc [NASDAQ:MCRB] has a current ratio of 2.71. Further, the Quick Ratio stands at 2.47, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 1.16.
Transactions by insiders
Recent insider trading involved Shaff Eric D., CEO and President, that happened on Feb 16 when 11549.0 shares were sold., Ege David S. completed a deal on Feb 16 to sell 5010.0 shares. Meanwhile, von Moltke Lisa sold 4400.0 shares on Feb 16.
